Truist Financial Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price objective dropped by equities researchers at Truist Financial from $43.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 156.15% from the company’s current price.

Several other equities research analysts have also weighed in on the stock. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Finally, Piper Sandler cut their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Keros Therapeutics Stock Down 2.2 %

Shares of KROS opened at $9.76 on Wednesday. The company has a 50-day moving average price of $10.91 and a two-hundred day moving average price of $31.87. The stock has a market cap of $395.89 million, a price-to-earnings ratio of -1.87 and a beta of 1.39. Keros Therapeutics has a 12 month low of $9.37 and a 12 month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Equities research analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Geode Capital Management LLC boosted its stake in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the last quarter. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the fourth quarter valued at approximately $388,000. Barclays PLC boosted its stake in Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after acquiring an additional 35,022 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Keros Therapeutics during the 4th quarter worth $461,000. Finally, Emerald Advisers LLC grew its holdings in Keros Therapeutics by 57.3% during the 4th quarter. Emerald Advisers LLC now owns 244,633 shares of the company’s stock worth $3,873,000 after acquiring an additional 89,088 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.